In rat studies, BPC-157 demonstrated healing effects in various colitis models, including cysteamine-induced colitis, improved intestinal anastomosis healing, and promoted closure of gastrointestinal fistulascomplications relevant to Crohn's disease.[4][5][3] The proposed mechanisms include interaction with the nitric oxide system, angiogenic effects, endothelium protection, and modulation of growth factor expression.[1][6] Critical limitations include the lack of published results from controlled human trials, absence of FDA approval, and concerns about products being sold online without regulatory oversight.[2] The peptide was temporarily banned by the World Anti-Doping Agency in 2022, though it is not currently listed as banned.[2] Given these limitations, BPC-157 cannot be recommended as standard therapy for ulcerative colitis or Crohn's disease based on current evidence

Compounded GLP-1s for weight loss, such as compounded semaglutide and compounded tirzepatide, boomed in popularity over the past few years during shortages of name-brand GLP-1s
Mechanistically, SLC25A39 overexpression maintains mitochondrial function, while its deficiency disrupts mitochondrial protein import and complex I activity, resulting in excessive ROS generation, loss of mitochondrial membrane potential, DNA damage, ATP depletion, and impaired electron transport, ultimately triggering apoptosis
Similarly, online questionnaires have found a high prevalence of migraine-like headaches among patients with mitochondrial disease (66)
References Smith RG et al., J Clin Endocrinol Metab , 2000 Nass R et al., J Clin Endocrinol Metab , 2008 Kojima M & Kangawa K, Nature , 1999 PubChem Database MK-677 Entry Conclusion Both MK-677 (Ibutamoren) and MK-777 (Acetamoren) stimulate the same GH pathway one with nearly 30 years of data, the other just beginning its research journey